Nasus Pharma Ltd (NSRX) Financial Statements
Nasus Pharma Ltd (NSRX) files with the U.S. Securities and Exchange Commission under CIK 0002029039. 10KGenie shows its annual statements from SEC filings.
Key Figures, Fiscal Year 2025
- Revenue
- $1.24 billion
- Net Income
- -$5.86 million
- Total Assets
- $5.00 million
- Net Cash from Operations
- -$4.92 million
Fiscal year ended Dec 31, 2025. Latest periodic SEC filing: Mar 25, 2026. Source: SEC filings (EDGAR XBRL).
Open the full financial statements for NSRX in 10KGenie
Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History